ADCT vs AREC Comparison

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

American Resources Corp constructs and/or purchases and manages a chain of combined gasoline, diesel and natural gas (NG) fueling and service stations; construct conversion factories to convert NG to liquefied natural gas (LNG) and compressed natural gas (CNG); and construct conversion factories to retrofit vehicles currently using gasoline or diesel fuel to also run on NG in the United States and also to build a convenience store to serve its customers in each of its locations. Its segments are AIC focused on the extraction, processing, transportation, and distribution of coal for a variety of industries, with a focus on metallurgical quality coal to the steel industry; RLMT; and EMC.